HMGB1 and Duchenne muscular dystrophy: Further studies are necessary to elucidate whether the redox status of HMGB1 is rebalanced after AAV microdystrophin treatment and to determine whether circulating HMGB1 or disulfide HMGB1 levels could be an effective surrogate biomarker for DMD treatments currently being tested.